ProQR Therapeutics (NASDAQ:PRQR) Releases Quarterly Earnings Results, Misses Expectations By $0.01 EPS

ProQR Therapeutics (NASDAQ:PRQR) announced its earnings results on Thursday. The biopharmaceutical company reported ($0.09) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.01), FiscalAI reports. ProQR Therapeutics had a negative return on equity of 58.70% and a negative net margin of 273.20%.The company had revenue of $5.50 million for the quarter, compared to the consensus estimate of $6.12 million.

ProQR Therapeutics Stock Performance

Shares of PRQR stock traded up $0.10 during mid-day trading on Friday, reaching $1.82. The company’s stock had a trading volume of 436,113 shares, compared to its average volume of 412,185. The firm’s 50-day moving average is $1.65 and its two-hundred day moving average is $2.07. The company has a market cap of $190.96 million, a P/E ratio of -3.88 and a beta of 0.21. ProQR Therapeutics has a 1-year low of $1.07 and a 1-year high of $3.10.

Wall Street Analyst Weigh In

Several analysts have issued reports on the stock. Oppenheimer started coverage on shares of ProQR Therapeutics in a research report on Thursday. They issued an “outperform” rating and a $9.00 price target on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of ProQR Therapeutics in a research note on Thursday, January 22nd. Zacks Research raised ProQR Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Thursday, November 13th. Finally, Citigroup restated a “market outperform” rating on shares of ProQR Therapeutics in a research note on Friday. Seven investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, ProQR Therapeutics has a consensus rating of “Moderate Buy” and an average target price of $7.67.

Institutional Trading of ProQR Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Osaic Holdings Inc. raised its position in ProQR Therapeutics by 59.6% in the second quarter. Osaic Holdings Inc. now owns 12,050 shares of the biopharmaceutical company’s stock worth $25,000 after purchasing an additional 4,500 shares in the last quarter. Guggenheim Capital LLC bought a new stake in shares of ProQR Therapeutics in the 4th quarter valued at approximately $35,000. Invesco Ltd. acquired a new position in shares of ProQR Therapeutics in the 4th quarter worth approximately $51,000. Simplex Trading LLC raised its holdings in shares of ProQR Therapeutics by 44,169.0% in the 4th quarter. Simplex Trading LLC now owns 44,269 shares of the biopharmaceutical company’s stock worth $89,000 after buying an additional 44,169 shares in the last quarter. Finally, Persistent Asset Partners Ltd lifted its position in shares of ProQR Therapeutics by 24.5% during the 4th quarter. Persistent Asset Partners Ltd now owns 45,154 shares of the biopharmaceutical company’s stock worth $91,000 after buying an additional 8,874 shares during the period. Institutional investors own 32.65% of the company’s stock.

About ProQR Therapeutics

ProQR Therapeutics N.V. is a clinical-stage biotechnology company dedicated to developing RNA-based therapies for severe genetic diseases. Utilizing its proprietary Axiomer® RNA editing platform, ProQR aims to correct disease-causing mutations directly at the messenger RNA level. The company’s pipeline features several investigational candidates, including sepofarsen (formerly QR-110) for Leber congenital amaurosis type 10, QR-421a targeting Usher syndrome and certain forms of retinitis pigmentosa, and QR-313 for dystrophic epidermolysis bullosa.

Founded in 2012 and headquartered in Leiden, the Netherlands, ProQR maintains a significant presence in Cambridge, Massachusetts, to support its clinical research and regulatory initiatives.